Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer by Lee, C K et al.
Self-reported health-related quality of life is an independent
predictor of chemotherapy treatment benefit and toxicity in
women with advanced breast cancer
CK Lee*,1, MR Stockler
1,2, AS Coates
1,3, V Gebski
1, SJ Lord
1 and RJ Simes
1,2 on behalf of Australian
New Zealand Breast Cancer Trials Group
1NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia;
2Sydney Cancer Centre – Royal Prince Alfred and Concord
Hospitals, Sydney, NSW, Australia;
3International Breast Cancer Study Group, Bern, Switzerland
BACKGROUND: Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify
patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL.
METHODS: We used data from three advanced breast cancer trials in which patients (n¼378) were treated with cyclophosphamide,
methotrexate and 5-fluouracil. Patients self-rated their QL using LASA scales for physical well-being (PWB), mood, pain, nausea/
vomiting, appetite and overall QL. Multivariable regression models were constructed to compare overall survival (OS), objective
tumour response (OTR), adverse events (AEs) and weight loss according to grouped QL scores.
RESULTS: Physical well-being, mood, appetite and overall QL were significant univariable predictors of OS. Physical well-being and
appetite remained significant after adjustment for baseline biomedical factors. Poor PWB was associated with lower OTR (odds ratio
(OR)¼0.21, 95% confidence interval (CI) 0.09–0.51), higher risk of non-haematological AEs (OR¼3.26, 95% CI 1.49–7.15) and
greater risk of weight loss (OR 2.37, 95% CI 1.12–5.01) compared with good PWB.
CONCLUSIONS: In women with advanced breast cancer, PWB and appetite are predictors of chemotherapy response and toxicity as
well as survival. Quality of life should be a routine clinical assessment to guide patient selection for chemotherapy and for stratification
of patients in clinical trials.
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In advanced breast cancer, the primary goals of treatment are to
prolong and improve quality of life (QL) because the disease is
generally incurable. In a pivotal study conducted by Coates et al
(1987), patient-rated QL improved significantly on average in
women with advanced breast cancer receiving palliative chemo-
therapy, and both baseline QL scores and subsequent changes
were prognostic for survival (Coates et al, 1992). Although
chemotherapy is effective in relieving cancer-related symptoms,
these average benefits may not accrue to all patients and may in
some cases be offset by the significant physical and psychological
side-effects. Therefore, appropriate selection of patients for
chemotherapy is important to increase the likelihood that its
benefits will likely outweigh its harms.
Determination of the prognosis of patients with advanced breast
cancer can provide valuable information to guide oncologists in
deciding whether to offer palliative chemotherapy. Oncologists
consider a range of patient and disease characteristics such as age,
performance status, disease-free interval, hormone receptor status,
disease burden and prior adjuvant treatments (Hortobagyi et al,
1983; Gennari et al, 2005; Largillier et al, 2008). More recently,
patient’s self-reported health-related QL has also been recognised
as predictive of survival (Gotay et al, 2008; Quinten et al, 2009).
Poor QL before treatment is associated with shorter survival in
patients with advanced breast cancer (Coates et al, 1992; Efficace
et al, 2004; Winer et al, 2004; Gotay et al, 2008). However, there is
only limited evidence of the relationship between baseline QL and
response to chemotherapy (Seidman et al, 1995; Kramer et al,
2000; Winer et al, 2004) and treatment-related toxicity. Investiga-
tion of this issue is important because chemotherapy has a narrow
therapeutic index and a fine balance between benefits and harms.
Such information might help oncologists and patients to
individualise their treatment decisions.
In this study, we used data from three trials conducted by the
Australian New Zealand Breast Cancer Trials Group (ANZBCTG) to
validate earlier findings that baseline QL predicts overall survival
(OS) in advanced breast cancer and investigate the association
between baseline QL and chemotherapy response and toxicity.
MATERIALS AND METHODS
We used data from the common control arms of three randomised
controlled trials (RCTs) of first-line chemotherapy for patients
with advanced breast cancer conducted by ANZBCTG (ANZ8101,
ANZ8614 and ANZ0001). Trial participants were recruited
from participating hospitals across Australia and New Zealand.
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comparing the efficacy of doxorubicin and cyclophosphamide vs
cyclophosphamide, methotrexate, 5-fluouracil and prednisone
(CMFP), administered continuously vs intermittently (Coates
et al, 1987). ANZ8614, activated in January 1988, was a two-arm
RCT comparing the efficacy of mitoxantrone vs CMFP (Simes et al,
1994). ANZ0001, activated in June 2001, was a three-arm RCT
comparing the efficacy of intermittent capecitabine vs continuous
capecitabine vs CMFP (Stockler et al, 2007).
All three trials included a measurement of patients’ self-reported
QL at baseline. Investigation of QL as a predictor of treatment
response or toxicity was not specified in the original trial protocols.
Patients
Patients had histologically confirmed breast carcinoma with
measurable or evaluable recurrent or metastatic disease; adequate
bone marrow, hepatic and renal function; and were available for
follow-up. Patients were excluded if they had received cytotoxic
chemotherapy for recurrent or metastatic disease or extensive
radiotherapy, or had a history of other cancer, diabetes mellitus or
cardiac failure.
Only patients assigned to the continuous CMFP in each of the
three trials were included in the present analysis. Patients assigned
to the intermittent CMFP arm of ANZ8101 were excluded from this
study because this treatment arm was inferior to the CMFP
regimen given continuously as in the other trials. All patients
provided written informed consent for participation in the trials.
Treatments
In each of the three trials, CMFP was administered in 28-day cycles
with oral cyclophosphamide (100mgm
 2) daily for 14 days;
intravenous methotrexate (40mgm
 2) and intravenous 5-fluor-
ouracil (600mgm
 2) on days 1 and 8. Oral prednisone
(40mgm
 2) for first 14 days was routinely administered in
patients from ANZ8101 and ANZ8614, and was optional in
ANZ0001. All patients continued the initial chemotherapy regimen
until disease progression, intolerance or unacceptable toxicity.
Therapy beyond disease progression was at the discretion of the
treating oncologist.
QL instruments
Patients self-reported their QL with five linear analogue self
assessment (LASA) scales that measured physical well-being
(PWB), mood, pain, nausea/vomiting and appetite (Priestman
et al, 1977; Coates et al, 1993), and a single summative
Table 1 Demographic characteristics and chemotherapy treatment profile
Characteristics Overall n (%) Good PWB
a n (%) Mid PWB
a n (%) Poor PWB
a n (%)
Age460 years 170 (45) 69 (47) 63 (44) 26 (41)
Post-menopausal 275 (73) 108 (74) 105 (74) 44 (70)
Performance status
0 123 (32) 69 (47) 37 (26) 11 (18)
1 153 (40) 54 (37) 69 (49) 21 (33)
2 74 (20) 16 (11) 30 (21) 21 (33)
3 25 (7) 7 (5) 6 (4) 8 (13)
4 2 (1) 0 (0) 0 (0) 2 (3)
Extent of advanced cancer
Local or regional disease only 46 (12) 20 (14) 16 (11) 6 (9)
Distant disease only 186 (49) 73 (50) 70 (49) 32 (51)
Locoregional and distant disease 146 (39) 53 (36) 56 (40) 25 (40)
Disease-free interval 42years 208 (55) 78 (53) 74 (52) 38 (60)
Hormone receptor status of primary breast tumour
ER+ 151 (40) 63 (43) 56 (39) 25 (40)
ER  101 (27) 38 (26) 37 (26) 20 (32)
PR+ 115 (30) 47 (32) 43 (30) 18 (29)
PR  111 (29) 43 (29) 42 (30) 22 (35)
Tissue sites of metastasis
b
Liver 148 (39) 56 (38) 50 (35) 26 (41)
Lung 123 (33) 32 (22) 59 (42) 25 (40)
Brain 12 (3) 4 (3) 4 (3) 3 (5)
Bone 256 (68) 96 (66) 99 (70) 44 (70)
Prior adjuvant chemotherapy 84 (22) 29 (20) 31 (22) 20 (32)
Prior endocrine therapy 292 (77) 108 (74) 108 (76) 54 (86)
Haemoglobinp12gdl
 1 132 (35) 42 (29) 52 (37) 24 (38)
Neutrophil47.5 10
9l
 1 46 (13) 14 (10) 16 (12) 9 (15)
Bilirubin415mmoll
 1 26 (7) 13 (9) 4 (3) 6 (10)
Alkaline phosphatase4125IUl
 1 199 (54) 66 (46) 79 (57) 38 (62)
Median number of cycles of CMFP treatment 5 6 5 3
Range of cycles of CMFP treatment 1–25 1–25 1–21 1–14
Percentage of cyclophosphamide received
c 90% 92% 88% 83%
Percentage of methotrexate received
c 92% 96% 89% 81%
Percentage of 5-fluouracil received
c 93% 95% 92% 81%
Abbreviations: CMFP¼cyclophosphamide, methotrexate, 5-fluouracil, prednisone chemotherapy; ER¼oestrogen receptor; PR¼progesterone receptor; PWB¼physical well-
being.
aGood PWB¼LASA score 0–25; mid PWB¼LASA score 26–65; poor PWB¼LASA score 66–100.
bMore than one site could have been involved, so percentages
sum to more than 100%.
cThe reported percentage is the median total dose of chemotherapy received as compared with the ideal dose calculated on the basis of the body-
surface area.
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scales were 100mm long and scores range from 0 (best) to 100
(worst).
For the purpose of our analysis, scores for each QL scale
were arbitrarily divided into three groups: good (0–25), mid
(26–65) or poor (66–100). The categorisation was selected to be
consistent with the cut-points used in a previous study (Coates
et al, 1992).
Treatment benefits
Treatment benefits were evaluated by measuring OS, progression-
free survival (PFS), objective tumour response (OTR) and
improvement in baseline body weight. OS and PFS were
measured from randomisation to the date of death or first
documented disease progression respectively. OTR rate was
measured as the proportion of patients with evaluable disease
Table 2 Univariable Cox regression analysis of survival (n¼378)
n (%) Hazard ratio (95% CI) P-value
(A) Baseline demographic and clinical characteristics
Age 460 (vs p60 years) 170 (45) 1.29 (1.04–1.60) 0.02
Post-menopausal 275 (73) 1.21 (0.95–1.55) 0.12
Performance status (PS)
PS 0 123 (32) 1.00 — 0.0007
PS 1 153 (40) 1.40 (1.09–1.80)
PS2 74 (20) 1.65 (1.21–2.23)
PS3 & PS4 27 (8) 2.08 (1.35–3.21)
Disease-free interval 4 2 years 208 (55) 1.19 (0.95–1.48) 0.13
Prior treatment
Prior adjuvant chemotherapy 84 (22) 0.89 (0.68–1.17) 0.4
Prior endocrine therapy 292 (77) 1.20 (0.94–1.55) 0.15
Hormone receptor status
ER  101 (27) 1.00 — 0.01
ER+ 151 (40) 0.72 (0.54–0.94)
ER unknown 126 (33) 1.00 (0.77–1.32)
PR  111 (29) 1.00 — 0.01
PR+ 115 (30) 0.85 (0.65–1.13)
PR unknown 152 (40) 1.27 (0.98–1.65)
Sites of metastasis
Presence of liver metastasis (vs none) 148 (39) 1.33 (1.07–1.66) 0.01
Presence of brain metastasis (vs none) 12 (3) 2.53 (1.37–4.67) 0.003
Presence of lung metastasis (vs none) 123 (33) 1.40 (1.11–1.75) 0.004
Presence of bone metastasis (vs none) 256 (68) 0.94 (0.75–1.17) 0.57
Haemoglobinp12gdl
 1 132 (35) 1.23 (0.99–1.53) 0.07
Neutrophil47.5 10
9l
 1 46 (13) 1.88 (1.36–2.60) o0.001
Bilirubin415mmoll
 1 26 (7) 1.89 (1.24–2.87) 0.003
Alkaline phosphatase 4125IUl
 1 199 (54) 1.31 (1.05–1.63) 0.02
(B) Baseline QL
a (LASA variables)
Physical well-being (PWB) o0.0001
Mid PWB (vs good PWB) 142 (40) 1.70 (1.33–2.18)
Poor PWB (vs good PWB) 63 (18) 2.04 (1.50–2.78)
Appetite o0.0001
Mid appetite (vs good appetite) 88 (25) 1.60 (1.23–2.08)
Poor appetite (vs good appetite) 44 (13) 2.10 (1.50–2.93)
Overall QL 0.0001
Mid overall (vs good overall) 142 (42) 1.71 (1.34–2.19)
Poor overall (vs good overall) 37 (11) 1.41 (0.96–2.06)
Mood 0.01
Mid mood (vs good mood) 151 (43) 1.44 (1.13–1.83)
Poor mood (vs good mood) 48 (14) 1.31 (0.94–1.84)
Pain 0.08
Mid pain (vs good pain) 113 (32) 1.16 (0.90–1.49)
Poor pain (vs good pain) 63 (18) 1.41 (1.05–1.91)
Nausea/vomiting 0.21
Mid nausea/vomiting (vs good nausea/vomiting) 49 (14) 1.30 (0.95–1.77)
Poor nausea/vomiting (vs good nausea/vomiting) 14 (4) 1.29 (0.73–2.28)
Abbreviations: CI¼confidence interval; ER¼oestrogen receptor; LASA¼linear analogue self-assessment; PR¼progesterone receptor; QL¼quality of life.
aGood QL¼LASA
score 0–25, Mid QL¼LASA score 26–65, Poor QL¼LASA score 66–100.
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Weight loss (vs stable or weight gain) was measured as the
proportion of patients with an average decrease in weight from
their baseline reading.
Treatment toxicity
Adverse events (AEs) were expressed as the proportion of patients
who developed any grade 3 or grade 4 toxicity during the first 4 cycles
of chemotherapy treatment. WorldH e a l t hO r g a n i s ation criteria
(Miller et al, 1981) were used for ANZ8101 and ANZ8614; National
Cancer Institute Common Toxicity Criteria (Arbuck et al, 1998) were
used for ANZ0001. Haematological (anaemia, neutropenia and
thrombocytopenia) and non-haematological (nausea, vomiting,
diarrhoea, stomatitis and alopecia) AEs were analysed separately.
Statistical analysis
Overall survival and PFS were estimated by the Kaplan–Meier
method, and differences between patients with good, mid and poor
levels for each QL scale at baseline were compared with the log-
rank test (Kaplan and Meier, 1958). Cox proportional-hazard
models were used to estimate differences in OS according to each
level of the QL scale (Cox, 1972). Multivariable analysis for OS was
first performed with backward stepwise selection of biomedical
variables only. Then, multivariable analysis for OS was repeated
with backward stepwise selection of biomedical and QL variables.
Only statistically significant variables (Po0.05) were retained in
the final multivariable models. As shown in a previous analysis
using the same data set (Lee et al, 2010), trial is a significant factor
for survival; thus we stratified for trial in all univariable and
multivariable analyses for this study. Formal tests to detect the
presence of collinearity between the different QL scales, and QL
scales and ECOG performance status were also performed
(Weissfeld, 1989).
Univariable analyses with logistic regression tested for associa-
tions between QL subscales and OTR, AE and weight loss.
Multivariable models for these outcomes were constructed to
estimate the effects of these QL subscales, adjusted for biomedical
variables found to be significant in Cox model for OS.
All analyses were two-sided with no adjustment for multiple compari-
sons. No imputation of missing baseline QL values was performed.
RESULTS
Biomedical and demographic characteristics
A total of 378 patients with a median follow-up of 4.8 years were
included in this pooled analysis. The number of patients from
ANZ8101, ANZ8614 and ANZ0001 were 75 (20%), 194 (51%) and
109 (29%), respectively. The median follow-up of these patients
from ANZ8101, ANZ8614 and ANZ0001 were 4.8 years
(range 0–4.8 years), 10.1 years (range 0–10.9 years) and 3.2 years
(range 0–4.8 years), respectively. Table 1 summarises the baseline
characteristics and the treatment profiles of these patients for the
overall cohort and according to the baseline PWB. Apart from
performance status and lung metastasis, distribution of baseline
characteristics was similar in patients with good, mid and poor
PWB. Similar patterns of baseline characteristics were observed for
other QL scales (data not shown).
Baseline QL scores
Baseline LASA scores for each QL scale were available for 89–94%
of the patients. The proportion of patients with self-rating for each
scale was 93% (PWB), 94% (mood), 93% (pain), 93% (nausea and
vomiting), 93% (appetite) and 89% (overall life quality). The
distribution of the three categories of LASA scores for each QL
subscale is shown in Table 2B.
CMFP treatment
Two patients randomised to CMFP chemotherapy in the
original trials did not receive the assigned treatment. The remaining
376 patients (99.5%) received a median five cycles of treatment. The
chemotherapy doses administered were between 90 and 93% of those
planned. Patients with good, mid and poor PWB received medians of
6, 5 and 3 cycles of CMFP, respectively (Table 1).
OS and PFS
Physical well-being, mood, appetite and overall QL were pre-
dictors of OS in the univariable analyses (Table 2B). Physical well-
being and appetite were independent predictors of survival in a
multivariable model with biomedical and QL variables (Table 3B).
Performance status was statistically significant in a multivariate
model with biomedical factors only (Table 3A), but was not
statistically significant in a multivariable model with bio-
medical and QL scales (Table 3B). Patients with good PWB at
baseline had a statistically significantly longer PFS and OS
compared with patients who had mid or poor PWB (Figure 1A
and B). The median OS for patients with good, mid and poor PWB
were 19, 11 and 9 months, respectively (log-rank Po0.0001).
Similar results were observed for patients with good, mid and poor
appetite (Figure 1C and D).
Significant collinearity was not detected between the different
QL scales or between QL scales and ECOG performance status
(results not shown).
Table 3 Multivariable Cox regression analyses of survival for demo-
graphic and baseline clinical characteristics, and for baseline demographic
and clinical characteristics and QL variables (n¼378)
Hazard ratio (95% CI) P-value
(A) ‘Best’ model with demographic and clinical characteristics only
Age 460 1.46 (1.16–1.84) 0.001
ER  1.00 — 0.002
ER+ 0.63 (0.47–0.84)
ER unknown 0.94 (0.70–1.25)
Neutrophil47.5 10
9l
 1 1.68 (1.18–2.40) 0.004
PS 0 1.00 — 0.005
PS1 1.44 (1.11–1.88)
PS2 1.60 (1.16–2.22)
PS3 & PS4 1.83 (1.14–2.93)
Presence of brain metastasis (vs none) 2.42 (1.28–4.57) 0.006
Presence of liver metastasis (vs none) 1.38 (1.08–1.77) 0.009
Alkaline phosphatase 4 125IUl
 1 1.31 (1.03–1.67) 0.03
(B) ‘Best’ model with demographic, clinical characteristics and QL variables
Neutrophil47.5 10
9l
 1 1.91 (1.31–2.79) 0.001
Age460 1.45 (1.14–1.83) 0.002
ER  1.00 — 0.004
ER+ 0.64 (0.47–0.87)
ER unknown 0.98 (0.72–1.33)
Good PWB
a 1.00 — 0.004
Mid PWB
a 1.45 (1.09–1.91)
Poor PWB
a 1.64 (1.12–2.40)
Presence of brain metastasis (vs none) 2.37 (1.21–4.64) 0.01
Alkaline phosphatase 4125IUl
 1 1.37 (1.08–1.74) 0.01
Good appetite
a 1.00 — 0.03
Mid appetite
a 1.36 (1.01–1.84)
Poor appetite
a 1.49 (0.98–2.24)
Abbreviations: CI¼confidence interval; ER¼oestrogen receptor; PWB¼physical
well-being; PS¼performance status; QL¼quality of life; ULN¼upper limit normal.
aGood PWB/appetite¼LASA score 0–25; mid PWB/appetite¼LASA score
26–65; poor PWB/appetite¼LASA score 66–100.
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sObjective tumour response
The OTR rates for patients with good, mid and poor PWB were 47,
32 and 18%, respectively (adjusted Ptrendo0.001; Figure 2A). For
patients with good, mid and poor appetite, the OTR rates were 41,
34 and 18% respectively (adjusted Ptrend¼0.02; Figure 2A).
Weight loss
Fifty-one percent of women experienced weight loss during
chemotherapy. Women with good PWB had a mean weight gain
during chemotherapy of 2%, but mean weight loss was 2% for
women with mid PWB and 4% for women with poor PWB,
Logrank P<0.0001
Trend P<0.0001
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Appetite score Median progression-free survival
(months; 95% CI)
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142 5 107 63 39 20 10
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Figure 1 Overall survival (A) and PFS (B) curves stratified by PWB score, and OS (C) and PFS (D) curves stratified by Appetite score.
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srespectively (adjusted Ptrend¼0.01; Figure 2B). For women with
good appetite, there was a mean weight gain of 0.5%, but mean
weight loss was 2% for women with mid appetite and 7% for
women with poor appetite (adjusted Ptrend¼0.006; Figure 2B).
Treatment toxicity
Non-haematological AE rates were statistically significantly
different for patients with good (16%), mid (31%) and poor
(38%) PWB (adjusted Ptrend¼0.002; Figure 2C). Grade-3 or 4
nausea and vomiting were reported in 19, 41 and 42%; diarrhoea in
9, 12 and 11%; and grade-3 and 4 stomatitis in 8, 11 and 17% of
patients with good, mid and poor PWB, respectively. Grade-3 and
4 alopecia rates were similar in the three PWB groups.
The rates of non-haematological AEs were not significantly
different in patients with good, mid and poor appetite (adjusted
Ptrend¼0.06; Figure 2B).
G r a d e - 3a n d4h a e m a t o l o g i c a lt o x i c i t yr a t e sw e r en o ta s s o c i a t e dw i t h
PWB (adjusted Ptrend¼0.92) or appetite scores (adjusted Ptrend¼0.60).
DISCUSSION
In this analysis of women treated with CMFP as first-line
chemotherapy for advanced breast cancer, patient self-reported
PWB and appetite at baseline were independent predictors
of OS and PFS. Women with poor PWB had a median OS that
was 10 months shorter, and a median PFS that was 5 months
shorter, than women with good PWB. Furthermore, women with
poor PWB had OTR rates 29% lower, weight loss rates 19% lower
and treatment-related non-haematological AE rates 22% higher
than women with good PWB. Similar findings were observed
for women with poor appetite compared with those who had
good appetite.
Our study also showed that women with poor QL derived less
benefit and experienced more toxicity when treated with
chemotherapy than women with good QL. Overall, women
reporting poor QL at baseline received 50% fewer cycles of
chemotherapy, were 20–30% less likely to benefit from che-
motherapy and experienced rates of non-haematological treatment
toxicity 20% higher than women reporting good QL at baseline.
This research adds to the growing evidence that QL is an
independent predictor of survival in advanced cancer. In a
systematic review of cancer trials, Gotay et al (2008) reported that
36 of 39 trials showed an association between QL and survival.
Specific QL measures most frequently identified in these trials
were overall QL, physical well being, appetite loss and pain.
Another meta-analysis using data from 30 cancer trials produced a
multivariable model that identified impaired physical functioning,
pain and appetite loss as independent predictors of survival in
addition to established biomedical factors (Quinten et al, 2009).
Individual trials in advanced breast cancer have shown similar
findings with PWB (Coates et al, 1992), appetite loss (Efficace et al,
2004), pain (Kramer et al, 2000) and overall QL (Seidman et al,
1995; Winer et al, 2004) all reported as independent predictors
of survival. This study validates the prognostic significance of
self-reported QL, and specifically of PWB and appetite, as
predictors of survival in advanced breast cancer.
Furthermore, our findings raise the important question of
whether measurement of baseline QL can be used to improve the
selection of patients for chemotherapy. To date, few studies have
investigated baseline QL as predictor of treatment benefit and/or
adj OR* = 0.53
adj OR* = 0.21
OR = 0.51
OR = 0.25
adj P* < 0.0001
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
PWB
adj OR* = 0.81
adj OR* = 0.27
OR = 0.74
OR = 0.33
adj P* = 0.02
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
Appetite
OR = 1.51
adj OR* = 1.73
OR = 2.16
adj OR* = 2.37
adj P* = 0.01
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
PWB
OR = 1.55
adj OR* = 1.84
OR = 2.61
adj OR* = 2.65
adj P* = 0.006
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
Appetite
Good Poor Mid Good Poor Mid Good Poor Mid
Good Poor Mid Good Poor Mid
Good Poor Mid
adj OR* = 2.31
adj OR* = 3.26
OR = 2.32
OR = 3.22
adj P* = 0.002
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
PWB
adj OR* = 1.35
adj OR* = 2.13
OR = 2.38
OR = 1.48
adj P* = 0.06
0
20
40
60
80
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
Appetite
C
B A
Figure 2 (A) Proportion of OTR stratified by PWB and Appetite scores. (B) Proportion with weight loss during chemotherapy stratified by PWB and
Appetite scores. (C) Proportion with grade-3/4 non-haematological toxicity stratified by PWB and Appetite scores (*QL adjusted for performance status,
age, liver, and brain metastasis, oestrogen receptor status, neutrophil, serum alkaline phosphatase and trial enrolment).
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stoxicity in advanced breast cancer. Kramer et al (2000) reported an
association between QL (dyspnoea, fatigue and overall QL) and
tumour response in their analysis of 187 women treated with
paclitaxel or doxorubicin, but selection of specific QL scales as
independent predictors in the final multivariable model was
reported as unstable because of multi-collinearity. They did not
examine associations between QL and toxicity in this analysis. Two
other studies reported no association between QL and tumour
response to chemotherapy (Seidman et al, 1995; Winer et al, 2004)
or treatment-related toxicity (Seidman et al, 1995). Possible
explanations for the differences between these results and our
study include small sample size (Seidman et al, 1995), the type of
QL instruments and QL subscales used, and the methods used to
assess tumour response.
The main strength of this study is the use of high-quality,
individual patient data from three successive randomised clinical
trials conducted by the same group. The pooled data set contains
well-documented demographic, clinical and QL characteristics of
trial participants who were treated with the same regimen of
chemotherapy. Women in this study were assigned chemotherapy
independent of their baseline QL. Follow-up and outcome data
were collected prospectively with rigorous quality control.
This study has several limitations. First, our findings are
from women with advanced breast cancer who were treated
with CMFP. They may differ with other chemotherapy regimens or
for other cancers (Quinten et al, 2009). Second, the results are
not generalisable to women with early-stage breast cancer who do
not have tumour-related symptoms (Coates et al, 2000;
Goodwin et al, 2004; Gotay et al, 2008). Finally, this analysis was
conducted post hoc using available trial data and therefore should
be regarded as hypothesis-generating for future studies, rather
than definitive.
If our findings are confirmed, trials of new treatment
approaches should be investigated for women with poor QL.
These trials could address the value of any chemotherapy vs none,
of less intense vs standard-intensity chemotherapy, or of
chemotherapeutic or biological agents with a more favourable
therapeutic–toxic ratio. Outcomes, which incorporate both
survival time and QL, such as quality-adjusted PFS and OS, may
be more relevant measures of treatment benefit in these women.
The results of this study also suggest the value of stratifying
patients by their baseline QL for future randomised trials in
advanced breast cancer.
The primary goal of chemotherapy in advanced breast cancer is
to prolong and improve QL. Our findings suggest that women with
poor QL derive less benefit from chemotherapy and have increased
risks of toxicity than women with good QL. This analysis should be
regarded as hypothesis-generating and future studies that examine
the role of chemotherapy in advanced breast cancer patients with
poor QL are warranted.
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